The authority has upheld the order by the state’s appellate authority in June. The company has been held responsible for the violation of the Drugs & Cosmetic Act and the rules framed in 1945.
An FDA official said, “The action is with regard to a few batches of baby powder made in 2007, the shelf life of which had ended in July 2010. The FDA, in its first order in April to cancel the licence, and the subsequent ruling by the appellate authority, had claimed 1.6 million were exposed to cancer following the overuse of ethylene oxide for sterilisation.’’
A J&J India spokesman said, ‘’It is inappropriate to comment since the matter is sub judice.’’
However, the manufacturing was restored after the high court in September last year on a petition filed by J&J India to approach it to the licensing authority.
The official added that notwithstanding the March 15 order issued by the licensing authority the production will continue as J&J India has been given time till April 21 to explore legal course of action.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)